Table 2.
Keratin based biomaterials for various biomedical applications.
COMPOSITION | PROCESSING CONDITIONS | APPLICATIONS | REF | ||
---|---|---|---|---|---|
1. | Keratin dialysate (aq) with alkaline keratin dialysate | Glycerol (1%) was used as a softening agent. Curing of aqueous/alkaline keratin dialysate for 2 h at 100 °C. | Wound healing of corneal epithelial was observed in vitro | [177] | |
2. | Photo active keratin derived films | Films were doped with varying concentrations of methylene blue | Photodynamic therapy treatment, wound healing, tissue engineering | [178] | |
3. | Keratin film crosslinked by transglutaminase (TG) | 18 h treatment with TGase (30 U/g keratin) at 40 °C | Drug delivery, improve stability in artificial gastric juice environment | [179] | |
4. | Photo cross-linkable keratin-polyethylene glycol (PEG) hydrogels via the thiol-norborene “click” reaction | Thiol–norborene click reaction to fabricate keratin-polyethylene glycol (PEG) hydrogels. Eosin Y used as a photoinitiator |
2-D & 3-D cell culture substrates, microfabrication techniques such as photopatterning, wet spinning. | [180] | |
5. | Keratin film | Mixing ratios of keratin dialysate and alkaline keratin dialysate were 100, 90/10, 80/20, 70/30 and 50/50. | Reconstruction of ocular surface | [126] | |
6. | Keratin film | Glycerol and shindai keratin dried for about 24 h in a 50 °C ventilated oven. | These films continuously released loaded Rhodamine B for 12 h. | [181] | |
7. | Keratin, chitosan/gelatine 1:1:2 (w/w) | Gelatine concentration in solution was 5 mg/ml. Keratin & chitosan was 2.5 mg/ml each. Frozen at −40 °C |
soft tissue engineering | [182] | |
8. | Keratin -chitosan | CH solutions 2% (w/v), ethylene glycol (1.5 ml). | Wound dressing material | [183] | |
9. | PLA/chitosan/keratin composites | A 111: PLA (70%), chitosan (30%). A121: PLA (68%), chitosan (30%), keratin (2%). A131: PLA (66%), chitosan (30%), keratin (4%) |
Facilitates attachment and proliferation of osteoblast | [184] | |
10. | Keratin/poly (vinyl alcohol) composite | 10% keratin poly (vinyl alcohol) cross linked with 10% glyoxal | Nano fibres with high optical transmittance | [185] | |
11. | Keratin wound dressing | Porcine lethal extremity hemorrhage model | As hemostatic material | [186] | |
12. | Keratin gel | Feather-keratin derived hydrogel | The drug release rate was 97% at pH 8.4 for 24 h. | [187] | |
13. | Keratin gel | Human hair keratin alkylation | Act as a substrate for cellular attachment and proliferation, delivery of therapeutic agents | [188] | |
14. | Hydrogels in injectable forms | - | For repairing cardiac tissue after myocardial infarction. | [189] | |
15. | Keratin hydrogel | Glycerol (3%) to formulate 20% (w/v) solution. | Pupal tissue regeneration | [190] | |
16. | Keratin hydrogel | - | Fibroblasts culturing | [191] | |
17. | Recombinant keratin proteins | Two recombinant trichocyte keratins expressed by using a bacterial expression system. Recombinant keratin nanoparticles prepared by ultrasonic dispersion technique. |
Dermal wound healing | [192] | |
18. | Keratin hydrogel | Konjac glucomannan (KGM), human hair proteins (KER), ethanolic extract of Avena sativa (OAT) | Dressing material for diabetic wounds. | [193] | |
19. | Keratin based therapeutic dermal patches | Mixing keratin and exopolysaccharide solutions in defined concentrations. Blended solution exposed to −20 °C for 3 days followed by placing in 90% ethanol containing 1% CaCl₂ for 15 min. Incubation of frozen dermal patches at 37 °C. |
Wound healing | [194] | |
20. | Keratin/poly (vinyl alcohol) nanofibers | Keratose/PVA mass ratios (1:1, 1:3, 1:5 and 1:7). Electrospinning parameters (voltage, flow rate, tip, and receptor distance) were optimized. Collection of keratose/PVA blended nanofibers on nylon gauze followed by drying at room temperature. |
Tissue engineering. | [195] | |
21. | Keratin derived eco-friendly bioplastic film | Bioplastic film fabrication using glycerol (3.5%), microcrystalline cellulose (0.2%) in NaOH at 60 °C for 48 h. | Biopolymer, biomedical and pharmaceutical industries. | [196] |